Skip to main content

Andrew Fromkin

Equibles does not estimate personal net worth.

Get an email with a short summary when Immunovant, Inc. publishes a filing, an earnings call transcript or a press release.

Get IMVT alerts

About Andrew Fromkin

Andrew Fromkin is recorded as Board Member at Immunovant, Inc. (IMVT) since September 9, 2021. Immunovant, Inc. reported in an 8-K filed September 15, 2021 that Andrew Fromkin was appointed Series A preferred stock directors, effective September 9, 2021. Immunovant, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Immunovant, Inc. includes Eric Venker (CEO), Eric Venker, M.D. (CEO and Board Member), Eric Venker, M.D., Pharm.D. (CEO) and 7 others.

“Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant, each to serve until his successor is duly elected and qualified or until his earlier death, resignation or removal.”
Immunovant, Inc. Form 8-K, filed September 15, 2021 · Read the filing

Affiliation history

Company network

Current role

Biotechnology · Healthcare

Board Member

2021-09-09–present

Leadership on record at Immunovant, Inc.

Recent activity